Seeing Is Believing
Currently out of the existing stock ratings of Matt Miksic, 239 are a BUY (81.02%), 38 are a HOLD (12.88%), 18 are a SELL (6.1%).
Analyst Matt Miksic, currently employed at BARCLAYS, carries an average stock price target met ratio of 56.03% that have a potential upside of 18.58% achieved within 324 days.
Matt Miksic’s has documented 608 price targets and ratings displayed on 29 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BAX, Baxter International at 10-Mar-2025.
Analyst best performing recommendations are on ISRG (INTUITIVE SURGICAL).
The best stock recommendation documented was for ISRG (INTUITIVE SURGICAL) at 10/17/2022. The price target of $235 was fulfilled within 8 days with a profit of $44.88 (23.61%) receiving and performance score of 29.51.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$160
$29.18 (22.31%)
$127
27 days ago
(04-Mar-2025)
14/16 (87.5%)
$19.78 (14.11%)
487
Buy
$158
$27.18 (20.78%)
$149
2 months 4 days ago
(27-Jan-2025)
19/23 (82.61%)
$28.57 (22.07%)
465
Buy
$148
$17.18 (13.13%)
$146
2 months 8 days ago
(23-Jan-2025)
11/13 (84.62%)
$24.78 (20.11%)
403
Buy
$135
$4.18 (3.20%)
$115
2 months 8 days ago
(23-Jan-2025)
14/14 (100%)
$11.78 (9.56%)
298
Buy
$135
$4.18 (3.20%)
$130
3 months 11 days ago
(20-Dec-2024)
17/18 (94.44%)
$21.37 (18.81%)
545
Which stock is Matt Miksic is most bullish on?
Which stock is Matt Miksic is most reserved on?
What Year was the first public recommendation made by Matt Miksic?